Stock Price & Analysis

Based on the provided data, ITCI stock is currently trading at $127.22 after Johnson & Johnson agreed to acquire the company for $132 per share in cash. Given the pending acquisition deal and current trading price near the acquisition price, holding the position is recommended as there's limited upside potential of approximately 3.8% to reach the deal price.

Multiple analysts have downgraded ITCI to Hold following the acquisition announcement, including Canaccord, RBC Capital, and Piper Sandler. The consensus view suggests the $132 per share offer adequately reflects Caplyta's potential and expected cost synergies, with analysts not expecting a higher competing bid.

The stock's RSI of 83.73 indicates overbought conditions, while the MACD of 7.61 shows strong positive momentum. The stock is trading well above its 60-day SMA of $99.02, reflecting the significant premium from the acquisition announcement.

Based on recent news, ITCI stock price is expected to reach $132 per share in 2025 due to Johnson & Johnson's acquisition offer announced in January 2025. The acquisition deal values ITCI at approximately $14.6 billion, with J&J offering to acquire all outstanding shares at $132 per share in cash. Multiple analysts including Canaccord have adjusted their price targets to $132 to align with the acquisition price.

The S1 support level for ITCI Stock is $126.9 ,The R1 resistant level for ITCI Stock is $127.73.

As of the end of day on 2025-02-11, the price of ITCI Stock was $127.22.

The target price for ITCI Stock according to analyst rating is 129.46, with the highest price target at 140.00 and the lowest at 105.00. Analysts have a Moderate Buy rating on ITCI Stock overall.

The market cap of ITCI is $13.5B.

Based on the recent data and market developments, ITCI is currently fairly valued following Johnson & Johnson's acquisition announcement. Here's why:

Acquisition Details JNJ agreed to acquire ITCI for $132.00 per share in cash, representing a significant premium to its previous trading levels. This acquisition values ITCI at approximately $14.6 billion.

Analyst Consensus Multiple analysts have downgraded ITCI to Hold following the acquisition news:

• Canaccord downgraded from Buy to Hold, raising target to $132 from $119
• RBC Capital downgraded to Sector Perform from Outperform
• Piper Sandler downgraded to Neutral from Overweight

Valuation Assessment The stock is trading near the acquisition price of $132, suggesting the market believes the deal will close as announced. The premium offered by JNJ adequately reflects:

• Caplyta's market potential
• Expected cost synergies post-acquisition
• Fair value considering current market conditions

Conclusion With the stock trading close to the acquisition price and multiple analyst downgrades, ITCI appears fairly valued at current levels. There's limited upside potential unless a competing bid emerges, which analysts consider unlikely given the substantial premium offered by JNJ.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.

Based on recent developments, ITCI's stock price is projected to reach $132 by early 2025 due to Johnson & Johnson's acquisition agreement at $132 per share in cash. The acquisition deal, valued at approximately $14.6 billion, demonstrates J&J's strategic expansion in CNS therapeutics and sets a firm price ceiling. Given J&J's strong financial position and commitment to 5-7% growth through 2030, the acquisition is highly likely to complete successfully, making $132 the definitive price target.

ITCI has a total of 610 employees.